BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $13.83 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have covered the stock in the last year is $13.83.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 15.4% in the 4th quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after acquiring an additional 2,371,401 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares in the last quarter. Braidwell LP lifted its stake in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares in the last quarter. Kynam Capital Management LP lifted its stake in BioCryst Pharmaceuticals by 46.8% in the 4th quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company’s stock valued at $27,554,000 after acquiring an additional 1,466,807 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C raised its stake in shares of BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after purchasing an additional 1,964,000 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 1.2 %

BioCryst Pharmaceuticals stock opened at $4.16 on Tuesday. The firm has a market capitalization of $857.58 million, a P/E ratio of -3.46 and a beta of 1.90. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.06. The business has a 50-day moving average of $5.13 and a 200-day moving average of $5.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. Research analysts anticipate that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.